Insider Selling: Veracyte, Inc. (NASDAQ:VCYT) Insider Sells $314,475.03 in Stock

Veracyte, Inc. (NASDAQ:VCYT) insider Giulia C. Kennedy sold 9,081 shares of the firm’s stock in a transaction that occurred on Friday, June 4th. The stock was sold at an average price of $34.63, for a total transaction of $314,475.03. Following the completion of the transaction, the insider now directly owns 57,218 shares of the company’s stock, valued at $1,981,459.34. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Veracyte stock opened at $36.69 on Friday. The firm’s fifty day moving average is $43.98. The stock has a market cap of $2.47 billion, a PE ratio of -33.35 and a beta of 0.73. Veracyte, Inc. has a fifty-two week low of $22.69 and a fifty-two week high of $86.03.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings data on Monday, May 10th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. The firm had revenue of $36.70 million for the quarter, compared to analysts’ expectations of $34.52 million. Veracyte had a negative net margin of 52.87% and a negative return on equity of 5.91%. Equities research analysts forecast that Veracyte, Inc. will post -0.79 earnings per share for the current fiscal year.

Several research analysts recently commented on the stock. Truist Securities cut their price objective on shares of Veracyte from $84.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday, May 18th. Morgan Stanley lowered their target price on shares of Veracyte from $65.00 to $45.00 and set an “underweight” rating on the stock in a research note on Wednesday, May 12th. Needham & Company LLC lowered their target price on shares of Veracyte from $88.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, May 11th. Zacks Investment Research cut shares of Veracyte from a “hold” rating to a “sell” rating in a research note on Wednesday, April 21st. Finally, TheStreet cut shares of Veracyte from a “c-” rating to a “d+” rating in a research note on Wednesday, May 26th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. Veracyte presently has a consensus rating of “Buy” and a consensus target price of $54.67.

A number of large investors have recently modified their holdings of VCYT. Group One Trading L.P. raised its position in Veracyte by 227.3% in the 1st quarter. Group One Trading L.P. now owns 504 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 900 shares during the period. Sowell Financial Services LLC purchased a new position in Veracyte in the 1st quarter worth $33,000. Wealthcare Advisory Partners LLC purchased a new position in Veracyte in the 1st quarter worth $46,000. Lazard Asset Management LLC purchased a new position in Veracyte in the 4th quarter worth $60,000. Finally, NEXT Financial Group Inc raised its position in Veracyte by 337.0% in the 4th quarter. NEXT Financial Group Inc now owns 1,311 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 1,011 shares during the period.

Veracyte Company Profile

Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information.

See Also: Swap

Insider Buying and Selling by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.